AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Phoenix, Arizona--(Newsfile Corp. - January 4, 2022) - The Stock Day Podcast welcomed AGENTIX (OTC Pink: AGTX) ("the Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's background and current projects. "Agentix is a clinical stage biotechnology company committed to the development of therapies for metabolic diseases, including type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH)," shared Mazzocchi.

"Could you give us an update on any recent developments for your projects?" asked Jolly. "We have actually re-prioritized our clinical development efforts and strategically decided to focus strictly on the pharmaceutical applications of our technology," explained Mazzocchi. "We are pursuing the clinical development of two significant assets to treat these metabolic diseases," he continued. "To ensure the proper financing of the developments, we continue to strive towards an uplisting for the company to either the Nasdaq or NYSE."

The conversation then turned to potential development partnerships. "We recently announced two important alliances - one with the National Health Research Institute of Taiwan (NHRI), as well as the Research Triangle Institute (RTI)," said Mazzocchi.

Mazzocchi then elaborated on the reaction between cannabinoids and the natural receptors in the human body, and how one of the Company's technologies has proven it is able to lower blood glucose and improve insulin resistance in diabetic mice, while also lowering body weight and liver triglycerides. "We will be able to begin Phase I clinical trials within the next six to nine months," shared Mazzocchi, before discussing the Company's worldwide exclusive license and service agreement with RTI, which includes the commercialization of additional therapeutic assets.

"This really provides the company with a deeper pipeline of proprietary compounds that target several multibillion dollar indications," shared Mazzocchi. "With medical and pharmaceutical based cannabinoids, the key is that we have a better understanding today of the mechanism of action or how they react to our natural receptors, and that is what is driving this design and the development of the discovery process."

To close the interview, Mazzocchi elaborated on the Company's key milestones across 2022, including an uplisting to the Nasdaq or NYSE, as well as the continuation of their clinical development and protocols. "We are also trying to onboard a Chief Medical Officer and expand our management team, as well as additional independent directors for the board," said Mazzocchi. "Finally, we intend to extend our outreach to many potential strategic partners for commercialization."

To hear Rudy Mazzocchi's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8007151-agentix-discusses-2022-clinical-development-efforts-and-potential-uplisting-with-the-stock-day-po

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About AGENTIX

AGENTIX is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). AGENTIX has acquired and is commencing clinical evaluation of certain therapeutic assets exclusively licensed from the National Health Research Institute Taiwan (NHRI) and Research Triangle Institute (RTI), dba RTI International. For more information, please visit: www.agentixcorp.com.

CONTACT:

Rudy Mazzocchi
AGENTIX Corporation
Email: [email protected]
Ph: +1.321.229.2014

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our most recent Form 10-K in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials for any of our drug product candidates, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109003

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).